Connect Biopharma Presents Results From Phase 3 52-Week Study In Patients With AD Conducted By Simcere Pharma At 2026 AAD Annual Meeting
Benzinga Newsdesk 7 months ago
News
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients –– Rademikibart was well tolerated with safety comparable
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients –
– Rademikibart was well tolerated with safety comparable to placebo –
– Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting –
– Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET –
SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced results from a Phase 3 52-week study in patients with moderate‑to‑severe atopic dermatitis (AD) conducted by the Company's partner in China, Simcere Pharmaceutical Co., Ltd. (Simcere), which were presented during the Late‑Breaking Research session of the 2026 American Academy of Dermatology (AAD) Annual Meeting on March 28, 2026 in Denver, Colorado.